12th July 2022 | Pharma Updates
Alkem predicts an 8-11% growth rate for the Indian pharma industry
Alkem Laboratories believes that inflationary pressures and changing regulatory norms will be the main issues to watch out for when the pandemic eases, and that the Indian pharma business will recover to 8–11% growth rate with normalcy in activities.
M&A deal value in healthcare and pharma reaches a new high in the first half of 2022
The merger and acquisition (M&A) value in the first half of this calendar year reached a record high and will surpass the overall deal value of $3.35 billion in 2021 in India’s healthcare and pharmaceutical sector.
Zydus introduces generic sitagliptin for the treatment of type 2 diabetes
To combat type 2 diabetes in India, Zydus Lifesciences Ltd., a discovery-driven global life sciences firm, has introduced the generic sitagliptin under the brand names Sitaglyn and Siglyn.
Glenmark Pharma introduces gel for treatment of acne
Under the trade name MINYM, Glenmark Pharmaceuticals Ltd. debuted its topical Minocycline 4% gel for the management of moderate to severe acne. A robust antibacterial gel with a potent anti-inflammatory effect is minocycline gel, 4 percent.
Dr. Reddy's launches extended-release competitor to Pfizer's $200 million drug
In order to compete with Pfizer’s Toviaz, an extended-release overactive bladder medication, Dr. Reddy’s Laboratories has introduced a therapeutic generic version that potentially threaten more than $200 million in annual sales.
Roche reports positive findings from Hemlibra study for moderate or mild hemophilia A
Hemlibra continued to exhibit a favourable safety profile and efficient bleed control in patients with moderate or mild hemophilia A, without factor VIII inhibitors, as per data from the primary analysis of the phase III HAVEN 6 study.
First ever over-the-counter birth control pill to be reviewed by FDA
The first request for this kind of contraception was made by Perrigo Company, when it revealed that its unit HRA Pharma has petitioned the FDA to approve a daily birth control tablet for over-the-counter (OTC) sale.